,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['tnbc', 'mbc']
db04: tdxd vs tpc in her2-low mbc ~5m increase in pfs ~6m improvement in os (wow!) benefit seen in hr+ &amp;tnbc cohorts safety consistent &amp; manageable ild/pneumonitis mostly grade 1/2 although 3 associated deaths seen practice changing results! #asco22 
Breast Medical Oncologist @UNC_Lineberger Prior @JCO_ASCO editorial fellow. Views are my own.